Oral cannabinoids in people living with HIV on effective antiretroviral therapy: CTN PT028—study protocol for a pilot randomised trial to assess safety, tolerability and effect on immune activation

Cecilia T. Costiniuk(McGill University Health Centre), Mohammad‐Ali Jenabian(Université du Québec à Montréal)

BMJ Open

January 1, 2019

10.1136/bmjopen-2018-024793

Cited by 46

Related Papers

Immunosuppressive Tryptophan Catabolism and Gut Mucosal Dysfunction Following Early HIV Infection

|The Journal of Infectious Diseases|2015|126

Prevalence and Characterization of Subclinical Coronary Atherosclerotic Plaque with CT among Individuals with HIV: Results from the Canadian HIV and Aging Cohort Study

|Radiology|2021|37

Correction: Distinct Tryptophan Catabolism and Th17/Treg Balance in HIV Progressors and Elite Controllers

|PLoS ONE|2014|3

HPTN 069/ACTG A5305: phase II study of maraviroc-containing regimens for HIV PrEP in US women; Postive impact of a randomized controlled trial of the Uthando Lwethu ("Our Love") intervention on rates of couples HIV testing in rural South Africa

|Unknown|2016|1

Soluble CD40 Ligand Plays an Immunosuppressive Role in HIV Infection via IDO-Induced Tryptophan Catabolism, Treg Expansion and Microbial Translocation

|Data Archiving and Networked Services (DANS)|2013|0